1. moderate and severe covid-19. 2. the first four weeks after any vaccination/revaccination, including against covid-19, influenza, pneumococcal and other infections. 3. suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.). 4. patients requiring medications prohibited within the study. 5. medical history or previously diagnosed primary and secondary immunodeficiency. 6. medical history/suspicion of oncology of any localization (except for benign neoplasms). 7. exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study. 8. malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia. 9. allergy/ hypersensitivity to any of the components of the medications used in the treatment. 10. pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial. 11. use of medications listed in "prohibited concomitant therapy" within 4 weeks before the study entry. 12. patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs. 13. medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures. 14. participation in other clinical trials within 3 months prior to enrollment in this study. 15. the patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. immediate family is defined as a spouse, parents, children or siblings, whether natural or adopted. 16. the patient works for ooo "npf "materia medica holding" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.

1. moderate and severe covid-19. 2. the first four weeks after any vaccination/revaccination, including against covid-19, influenza, pneumococcal and other infections. 3. suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.). 4. patients requiring medications prohibited within the study. 5. medical history or previously diagnosed primary and secondary immunodeficiency. 6. medical history/suspicion of oncology of any localization (except for benign neoplasms). 7. exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study. 8. malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia. 9. allergy/ hypersensitivity to any of the components of the medications used in the treatment. 10. pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial. 11. use of medications listed in "prohibited concomitant therapy" within 4 weeks before the study entry. 12. patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs. 13. medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures. 14. participation in other clinical trials within 3 months prior to enrollment in this study. 15. the patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. immediate family is defined as a spouse, parents, children or siblings, whether natural or adopted. 16. the patient works for ooo "npf "materia medica holding" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.

1. moderate and severe covid-19. 2. the first four weeks after any vaccination/revaccination, including against covid-19, influenza, pneumococcal and other infections. 3. suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.). 4. patients requiring medications prohibited within the study. 5. medical history of or previously diagnosed primary and secondary immunodeficiency. 6. medical history/suspicion of oncology of any localization (except for benign neoplasms). 7. exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study. 8. malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia. 9. allergy/ hypersensitivity to any of the components of the medications used in the treatment. 10. pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial. 11. use of medications listed in "prohibited concomitant therapy" within 4 weeks before the study entry. 12. patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs. 13. medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures. 14. participation in other clinical trials within 3 months prior to enrollment in this study. 15. the patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. 'immediate relative' means husband/wife, parents, children, brother/sister regardless of whether they are natural or adopted. 16. the patient works for ooo "npf "materia medica holding" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.

1. moderate and severe covid-19. 2. the first four weeks after any vaccination/revaccination, including against covid-19, influenza, pneumococcal and other infections. 3. suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.). 4. patients requiring medications prohibited within the study. 5. medical history of or previously diagnosed primary and secondary immunodeficiency. 6. medical history/suspicion of oncology of any localization (except for benign neoplasms). 7. exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study. 8. malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia. 9. allergy/ hypersensitivity to any of the components of the medications used in the treatment. 10. pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial. 11. use of medications listed in "prohibited concomitant therapy" within 4 weeks before the study entry. 12. patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs. 13. medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures. 14. participation in other clinical trials within 3 months prior to enrollment in this study. 15. the patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. 'immediate relative' means husband/wife, parents, children, brother/sister regardless of whether they are natural or adopted. 16. the patient works for ooo "npf "materia medica holding" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.

moderate and severe covid-19. the first four weeks after any vaccination/revaccination, including against covid-19, influenza, pneumococcal and other infections. suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.). patients requiring medications prohibited within the study. medical history of or previously diagnosed primary and secondary immunodeficiency. medical history/suspicion of oncology of any localization (except for benign neoplasms). exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study. malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia. allergy/ hypersensitivity to any of the components of the medications used in the treatment. pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial. use of medications listed in "prohibited concomitant therapy" within 4 weeks before the study entry. patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs. medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures. participation in other clinical trials within 3 months prior to enrollment in this study. the patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. 'immediate relative' means husband/wife, parents, children, brother/sister regardless of whether they are natural or adopted. the patient works for ooo "npf "materia medica holding" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.

moderate and severe covid-19. the first four weeks after any vaccination/revaccination, including against covid-19, influenza, pneumococcal and other infections. suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.). patients requiring medications prohibited within the study. medical history of or previously diagnosed primary and secondary immunodeficiency. medical history/suspicion of oncology of any localization (except for benign neoplasms). exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study. malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia. allergy/ hypersensitivity to any of the components of the medications used in the treatment. pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial. use of medications listed in "prohibited concomitant therapy" within 4 weeks before the study entry. patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs. medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures. participation in other clinical trials within 3 months prior to enrollment in this study. the patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. 'immediate relative' means husband/wife, parents, children, brother/sister regardless of whether they are natural or adopted. the patient works for ooo "npf "materia medica holding" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.